Preeclampsia (PE) is a multisystem disorder that complicates around 3 % of pregnancies, with major long-term health complications for both women and children [1].

This serious vascular condition is the second leading cause of maternal mortality in developed countries and increases the risk of cardiovascular diseases even after pregnancy [2]. It often results in a premature delivery, preterm birth being the world's leading cause of neonatal morbidity and mortality [3], with a wide range of associated disorders, including intellectual disability or respiratory distress syndrome, among others [4].

The lack of accurate diagnostic and predictive tools is one of the main factors behind this high morbidity and mortality [5]. In this regard, the introduction of measurements of the angiogenic factors (AF) soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) has been a significant improvement [6], [7].

Although its use in current clinical practice is based on isolated measurements of serum concentration, the dynamic changes in AF experienced during pregnancy are currently being studied, as it is thought that they may be a useful tool for risk stratification, monitoring the progress of the disease and, therefore, improving its management and prognosis [8], [9].